2018 Cachexia Pipeline Insight Report, Featuring: Baxter Healthcare Corp, GSK, Novartis, Pfizer, Teijin Pharma, and more - ResearchAndMarkets.com

DUBLIN--()--The "Cachexia - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Cachexia development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Scope

  • The report provides a snapshot of the pipeline development for Cachexia
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Cachexia
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Cachexia
  • The report also covers the dormant and discontinued pipeline projects related to Cachexia

Companies Featured

  • Aphios Corp.
  • Baxter Healthcare Corporation
  • Cannabics Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • H & J CRO International Inc.
  • Helsinn Healthcare SA
  • MYOS RENS Technology Inc.
  • Novartis AG
  • Pfizer
  • Smartfish AS
  • Teijin Pharma Ltd.
  • VBS Pharmaceuticals

Key Topics Covered

1. Report Introduction

2. Cachexia Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Cachexia

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wrl6cw/2018_cachexia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drugs by Therapeutic Area

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drugs by Therapeutic Area